PD Dr. rer. nat. Robyn Laura Kosinsky
Group Leader

PD Dr. rer. nat. Robyn Laura Kosinsky

Robyn Laura Kosinsky was born in Emmerich am Rhein, Germany, in 1988. She obtained her Bachelor’s degrees in Life Sciences and Applied Biology at the HAN University of Applied Sciences, The Netherlands, and Bonn-Rhein-Sieg University of Applied Sciences, Germany. To understand disease-relevant molecular mechanisms, she completed her Master of Science in Molecular Medicine at the Georg-August University Göttingen, Germany. During her PhD, Robyn evaluated the function of a deubiquitinating enzyme in intestinal organ maintenance and the development of colorectal cancer (CRC) in the group of Dr. Steven A. Johnsen at the University Medical Center Göttingen. Afterwards, she acquired funding for women in leadership positions as well as further third-party funding to focus on epigenetic  mechanisms related to intestinal inflammation as well as inflammation-associated and sporadic CRC. Based on her dedication to teaching and her academic achievements, she was awarded the  Venia Legendi (habilitation) in Molecular Medicine in 2020.  To extend her knowledge on epigenetic (de)regulation in immune regulatory cells in chronic intestinal  inflammation, she acquired a Mildred-Scheel Postdoctoral Fellowship (Deutsche Krebshilfe). Under  the supervision of Dr. William A. Faubion she focused on T cell biology in Crohn’s disease within the  Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota, USA. At  the end of her research stay, she has obtained the rank of Adjunct Assistant Professor of Medicine at Mayo Clinic. In May 2022, Robyn assumed the position as a group leader at the Robert Bosch Center for Tumor Diseases where she and her team will elucidate epigenetic mechanisms in inflammation-driven tumorigenesis.

☛ Check out the Kosinsky Lab on Instagram


Relevant Own Publications

  • Bamidele AO, Mishra SK, Ramos GP, Hirsova P, Klatt EE, Abdelrahman LM, Sagstetter MR, Davidson HM, Fehrenbach PJ, Valenzuela-Pérez L, Kim Lee HS, Zhang S, Lopez AA, Kurdi AT, Westphal MS, Gonzalez MM, Gaballa JM, Kosinsky RL, Lee HE, Smyrk TC, Bantug G, Gades NM, Faubion WA Jr. Interleukin 21 Drives a Hypermetabolic State and CD4+ T-Cell-Associated Pathogenicity in Chronic Intestinal Inflammation. Gastroenterology. 2024 Jan 23:S0016-5085(24)00063-5. doi: 10.1053/j.gastro.2024.01.026. Epub ahead of print.

  • Kosinsky RL, Gonzalez MM, Saul D, Barros LL, Sagstetter MR, Fedyshyn Y, Nair A, Sun Z, Hamdan FH, Gibbons HR, Perez Pachon ME, Druliner BR, Johnsen SA, Faubion WA. The FOXP3+ Pro-Inflammatory T Cell: A Potential Therapeutic Target in Crohn's Disease. Gastroenterology. 2024 Jan 9:S0016-5085(24)00009-X. doi: 10.1053/j.gastro.2024.01.007. Epub ahead of print

  • Wang X, Kutschat AP, Aggrey-Fynn J, Hamdan FH, Graham RP, Wixom AQ, Souto Y, Ladigan-Badura S, Yonkus JA, Abdelrahman AM, Alva-Ruiz R, Gaedcke J, Ströbel P, Kosinsky RL, Wegwitz F, Hermann P, Truty MJ, Siveke JT, Hahn SA, Hessmann E, Johnsen SA, Najafova Z. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2023 Sep 1;21(9):881-891. doi: 10.1158/1541-7786.MCR-22-0916. PMID: 37279184.

  • Saul D, Kosinsky RL. Spatial transcriptomics herald a new era of transcriptome research. Clin Transl Med. 2023 May;13(5):e1264. doi: 10.1002/ctm2.1264. PMID: 37190941.
  • Hamdan FH, Abdelrahman AM, Kutschat AP, Wang X, Ekstrom TL, Jalan-Sakrikar N, Wegner Wippel C, Taheri N, Tamon L, Kopp W, Aggrey-Fynn J, Bhagwate AV, Alva- Ruiz R, Lynch I, Yonkus J, Kosinsky RL, Gaedcke J, Hahn SA, Siveke JT, Graham R, Najafova Z, Hessmann E, Truty MJ, Johnsen SA. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Gut. 2023 Jun;72(6):1174-1185. doi: 10.1136/gutjnl-2022-328154. Epub 2023 Mar 8. PMID: 36889906.

  • Dietlein N, Wang X, Metz J, Disson O, Shang F, Beyersdörffer C, Rodríguez Correa E, Lipka DB, Begus-Nahrmann Y, Kosinsky RL, Johnsen SA, Lecuit M, Höfer T, Rodewald HR. Usp22 is an intracellular regulator of systemic emergency hematopoiesis. Sci Immunol. 2022 Dec 16;7(78):eabq2061. doi: 10.1126/sciimmunol.abq2061. Epub 2022 Dec 9. PMID: 36490327.

  • Ramos GP, Bamidele AO, Klatt EE, Sagstetter MR, Kurdi AT, Hamdan FH, Kosinsky RL, Gaballa JM, Nair A, Sun Z, Dasari S, Lanza IR, Rozeveld CN, Schott MB, Urrutia G, Westphal MS, Clarkson BD, Howe CL, Marietta EV, Luckey DH, Murray JA, Gonzalez M, Braga Neto MB, Gibbons HR, Smyrk TC, Johnsen S, Lomberk G, Faubion WA. G9a Modulates Lipid Metabolism in CD4 T Cells to Regulate Intestinal Inflammation. Gastroenterology. 2023 Feb;164(2):256-271.e10. doi: 10.1053/j.gastro.2022.10.011. Epub 2022 Oct 20. PMID: 36272457.

  • Saul D, Kosinsky RL, Atkinson EJ, Doolittle ML, Zhang X, LeBrasseur NK, Pignolo RJ, Robbins PD, Niedernhofer LJ, Ikeno Y, Jurk D, Passos JF, Hickson LJ, Xue A, Monroe DG, Tchkonia T, Kirkland JL, Farr JN, Khosla S. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat Commun. 2022 Aug 16;13(1):4827. doi: 10.1038/s41467-022-32552-1. PMID: 35974106.

  • Kosinsky RL, Zerche M, Kutschat AP, Nair A, Ye Z, Saul D, von Heesen M, Friton JJ, Schwarzer AC, Paglilla N, Sheikh SZ, Wegwitz F, Sun Z, Ghadimi M, Newberry RD, Sartor RB, Faubion WA, Johnsen SA. RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease. Cell Death Differ. 2021 Nov;28(11):3161-3175. doi: 10.1038/s41418-021-00808-w. Epub 2021 Jun 4. PMID: 34088983.

  • Gonzalez MM, Bamidele AO, Svingen PA, Sagstetter MR, Smyrk TC, Gaballa JM, Hamdan FH, Kosinsky RL, Gibbons HR, Sun Z, Ye Z, Nair A, Ramos GP, Braga Neto MB, Wixom AQ, Mathison AJ, Johnsen SA, Urrutia R, Faubion WA Jr. BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease. J Clin Invest. 2021 Jun 15;131(12):e140755. doi: 10.1172/JCI140755. PMID: 34128475.

  • Kosinsky RL, Helms M, Zerche M, Wohn L, Dyas A, Prokakis E, Kazerouni ZB, Bedi U, Wegwitz F, Johnsen SA. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer. Cell Death Dis. 2019 Dec 4;10(12):911. doi: 10.1038/s41419-019-2141-9. PMID: 31801945.

  • Kosinsky RL, Zerche M, Saul D, Wang X, Wohn L, Wegwitz F, Begus-Nahrmann Y, Johnsen SA. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. Cell Death Differ. 2020 Apr;27(4):1328-1340. doi: 10.1038/s41418-019-0420-8. Epub 2019 Sep 17. PMID: 31527800.

  • Schneider D, Chua RL, Molitor N, Hamdan FH, Rettenmeier EM, Prokakis E, Mishra VK, Kari V, Wegwitz F, Johnsen SA, Kosinsky RL. The E3 ubiquitin ligase RNF40 suppresses apoptosis in colorectal cancer cells. Clin Epigenetics. 2019 Jul 2;11(1):98. doi: 10.1186/s13148-019-0698-x. PMID: 31266541.

  • Kosinsky RL, Chua RL, Qui M, Saul D, Mehlich D, Ströbel P, Schildhaus HU, Wegwitz F, Faubion WA, Johnsen SA. Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice. J Crohns Colitis. 2019 Mar 26;13(3):362-373. doi: 10.1093/ecco-jcc/jjy165. PMID: 30321325.

  • more ORCID https://orcid.org/0000-0003-2869-7762